Showing results (81-90 of 233) with videos related to

Sort By:
Pageof 24
Blood|October 30, 2016
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaYa-Wei Qiang, Shiqiao Ye, Yu Chen, et al.
Oncotarget|September 2, 2015
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman diseaseFrits van Rhee, Corey Casper, Peter M Voorhees, et al.
The Patient|March 5, 2015
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of SiltuximabFrits van Rhee, Margaret Rothman, Kai Fai Ho, et al.
International Journal of Molecular Sciences|December 23, 2022
Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate ModelTarun K Garg, Sarita Garg, Isabelle R Miousse, et al.
Blood|January 27, 2005
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesFrits van Rhee, Susann M Szmania, Fenghuang Zhan, et al.
American Journal of Hematology|March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseRakesh Bam, Wen Ling, Sharmin Khan, et al.
Radiation Research|December 7, 2023
Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body RadiationTarun K Garg, Sarita Garg, Isabelle R Miousse, et al.
British Journal of Haematology|May 4, 2022
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registryDavid C Fajgenbaum, Sheila K Pierson, Karan Kanhai, et al.
Blood|December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBart Barlogie, Guido Tricot, Erik Rasmussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman DiseaseCorey Casper, Shalini Chaturvedi, Nikhil Munshi, et al.
Pageof 24